Filing Flows › Adia Med (ADIA) › Q2 2026 › vs Q1 2026
Adia Med (ADIA) Q2 2026 vs Q1 2026 (quarter over quarter)
Adia Med's revenue rose $309K (+175%) from $176K in Q1 2026 to $485K in Q2 2026. The biggest changes: Medical Procedures +$225K (+215%); Sales of Biologics +$82K (+117%); Shipping and Delivery +$2K (+131%). Gross margin 58.2% against 38.3% (+19.9 pts).
Adia Med, Q2 2026: revenue $485K (+311% year over year), operating margin 10.7%, net earnings $40K, operating cash flow −$109K. The chart draws each line against Q1 2026, the increases inside each band.
Margins
| Q2 2026 | Q1 2026 | Change | |
|---|---|---|---|
| Gross margin | 58.2% | 38.3% | +19.9 pts |
| Operating margin | 10.7% | -86.2% | +96.9 pts |
| Net margin | 8.3% | -92.2% | +100.5 pts |
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Medical Procedures | $330K | $105K | $225K | +215% |
| Sales of Biologics | $152K | $70K | $82K | +117% |
| Shipping and Delivery | $4K | $2K | $2K | +131% |
| Revenue | $485K | $176K | $309K | +175% |
| Gross profit | $283K | $68K | $215K | +318% |
| Cost of revenue | $203K | $109K | $94K | +87% |
| Operating profit | $52K | −$152K | $204K | — |
| Operating expenses | $231K | $219K | $11K | +5% |
| Pre-tax earnings | $40K | −$163K | $203K | — |
| Other expense, net | $11K | $11K | $1K | +8% |
| Sales & marketing | $22K | $37K | −$15K | -39% |
| General & admin | $208K | $182K | $26K | +14% |
| Net earnings | $40K | −$163K | $203K | — |
| Operating cash sources | $151K | −$106K | $257K | — |
| Depreciation | $1K | $1K | $193 | +15% |
| Cash used in operations | $109K | $55K | $54K | +98% |
| Working capital & other | $151K | −$106K | $257K | — |
Questions
How much did Adia Med's revenue grow quarter over quarter in Q2 2026?
Adia Med's revenue rose $309K (+175%) from $176K in Q1 2026 to $485K in Q2 2026.
What drove Adia Med's revenue change in Q2 2026?
Medical Procedures +$225K (+215%); Sales of Biologics +$82K (+117%); Shipping and Delivery +$2K (+131%).